There are talks about growing pawpaws, a cut flower garden, hardscaping and more. There are hands-on workshops to make things ...

Mugs seem to be the gift that overstays its welcome before long. Sure, there's always a treasured few that you use with ...

From protein-filled meals to the benefits of lentils and intermittent fasting, the Classical world had strong opinions about ...

The annual MOSAIC job fair in New Westminster is an all ... contradicts him on one of his biggest campaign promises Elisabeth Moss took Handmaid’s Tale role to stop another actor getting the ...

Mosaic Youth Theatre of Detroit is bringing Shakespeare’s “Julius Caesar” to the D — quite literally. The theatre is reimagining the classic play in modern times, set in a Detroit high ...

Mosaic (MOS) came out with quarterly earnings of $0.49 per share, beating the Zacks Consensus Estimate of $0.39 per share. This compares to earnings of $0.65 per share a year ago. These figures ...

TAMPA, FL / ACCESS Newswire / May 6, 2025 / The Mosaic Company (NYSE:MOS) released its financial results for the first quarter of 2025. The company's earnings release and supplemental materials ...

Mosaic MOS is gearing up to announce its quarterly earnings on Tuesday, 2025-05-06. Here's a quick overview of what investors should know before the release. Analysts are estimating that Mosaic ...

The Rev. Otis Moss III, pastor at Trinity United Church of Christ in Chicago, acknowledged the museum’s value and is asking congregants to become members to support the museum, the Associated ...

Mosaic Therapeutics a UK-based oncology company has announced it has in-licensed two clinical-stage oncology programmes from Astex Pharmaceuticals. The agreement transforms Mosaic from a ...

Mosaic Therapeutics has secured the latest pieces in its combination medicine strategy by licensing two clinical stage tumor drugs from fellow British biotech Astex Pharmaceuticals. The small ...

In-licensing these clinical-stage assets has significantly de-risked and accelerated Mosaic’s development path; the compounds will be developed as proprietary combination therapies Syncona Ltd, ...